TrialCurveSCORES: reconstructed Kaplan–Meier curves
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Cancer. 2026 Jan 9;7(1):182–93. doi: 10.1038/s43018-025-01085-z |
|---|---|
| DOI | 10.1038/s43018-025-01085-z |
| Registry | NCT04908787 |
| Phase | Phase 3 |
| Conditions | Ovarian Cancer |
| Interventions | BD0801, Paclitaxel, Placebo, Topotecan, doxorubicin liposome |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Enrolment | 421 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival, final analysis — Full analysis set
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SV + CT 15.6 months; PBO + CT 14.0 months. Survival at 12 months: SV + CT 64%; PBO + CT 54%. Hazard ratio SV + CT vs PBO + CT 0.80 (95% CI 0.63–1.02).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SV + CT | 281 | 178 | 15.6 |
| PBO + CT | 140 | 101 | 14.0 |
- SV + CT vs PBO + CT: reconstructed HR 0.80 (95% CI 0.63–1.02)
Landmark survival (reconstructed)
| Time | SV + CT | PBO + CT |
|---|---|---|
| 6 mo | 83.3% | 74.1% |
| 12 mo | 64.1% | 54.4% |
| 18 mo | 43.8% | 40.6% |
| 24 mo | 32.9% | 22.0% |
| 36 mo | 21.7% | — |
Checks against the published figure
- SV + CT median: printed 15.3, reconstructed 15.6 pass
- PBO + CT median: printed 14, reconstructed 14 pass
- SV + CT events: printed 178, reconstructed 178 pass
- SV + CT n: printed 281, reconstructed 281 pass
- PBO + CT events: printed 101, reconstructed 101 pass
- PBO + CT n: printed 140, reconstructed 140 pass
- hazard ratio (direction inferred): printed 0.77, reconstructed 0.801 pass
Overall survival — Patients without subsequent antitumor therapy (hypothetical estimand supplementary analysis)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: SV + CT 22.3 months; PBO + CT 11.9 months. Survival at 12 months: SV + CT 67%; PBO + CT 48%. Hazard ratio SV + CT vs PBO + CT 0.64 (95% CI 0.44–0.93).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SV + CT | 281 | 75 | 22.3 |
| PBO + CT | 140 | 42 | 11.9 |
- SV + CT vs PBO + CT: reconstructed HR 0.64 (95% CI 0.44–0.93)
Landmark survival (reconstructed)
| Time | SV + CT | PBO + CT |
|---|---|---|
| 6 mo | 82.8% | 71.9% |
| 12 mo | 66.6% | 48.2% |
| 18 mo | 53.7% | 41.2% |
| 24 mo | 47.2% | 22.0% |
| 36 mo | 47.2% | — |
Checks against the published figure
- SV + CT median: printed 22.3, reconstructed 22.3 pass
- PBO + CT median: printed 11.9, reconstructed 11.9 pass
- SV + CT events: printed 75, reconstructed 75 pass
- SV + CT n: printed 281, reconstructed 281 pass
- PBO + CT events: printed 41, reconstructed 42 pass
- PBO + CT n: printed 140, reconstructed 140 pass
- hazard ratio (direction inferred): printed 0.59, reconstructed 0.638 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- Chemoradiotherapy ± simultaneous integrated boost in cervical cancer: Overall survival; Pelvic-specific PFS; Progression-free survival (PFS)
- PORTEC-3: Overall survival; Recurrence-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials